R-HU-EPO FOR ANEMIA OF PREMATURITY

早产儿贫血是红细胞输注的主要原因 在新生儿重症监护室。大多数极低出生体重儿 接受多次输血。促红细胞生成素生产不足以应对 贫血是导致早产儿闭经的因素之一。审判 对稳定的大龄婴儿给予r-Hu-EPO的研究表明，它是安全的和 有效治疗早产儿贫血。这项研究是为了 确定是否对极早产儿进行早期治疗 在减少输血方面的效果会比目前的 习惯于在出生后2-3周开始治疗。 现状：这项多中心研究可能不会在加州大学旧金山分校实施。 迄今开展的活动包括与r-HU-EPO有关的介绍和 出版物。

Anemia of prematurity is the major cause for red blood cell transfusions in the neonatal intensive care unit. Most very low birthweight infants receive multiple transfusions. Inadequate production of EPO in response to anemia is one of the factors contributing to amenia of prematurity. Trials of r-Hu-EPO given to stable, older infants have shown it to be a safe and effective treatment for anemia of prematurity. This study is undertaken to determine whether very early treatment of extremely premature infants with will have a greater effect in reducing transfusions than the current practice of beginning treatment at 2-3 weeks after birth. Status: This multi-centered study may not be implemented at UCSF. Activities undertaken to date include r-Hu-EPO related presentations and publications.